Macrogenics Inc (MGNX) concluded trading on Wednesday at a closing price of $3.35, with 0.47 million shares of worth about $1.58 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.55% during that period and on January 08, 2025 the price saw a loss of about -1.76%. Currently the company’s common shares owned by public are about 62.76M shares, out of which, 57.89M shares are available for trading.
Stock saw a price change of 3.08% in past 5 days and over the past one month there was a price change of -4.29%. Year-to-date (YTD), MGNX shares are showing a performance of 3.08% which decreased to -68.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.95 but also hit the highest price of $21.88 during that period. The average intraday trading volume for Macrogenics Inc shares is 570.63K. The stock is currently trading 1.58% above its 20-day simple moving average (SMA20), while that difference is down -4.55% for SMA50 and it goes to -42.67% lower than SMA200.
Macrogenics Inc (NASDAQ: MGNX) currently have 62.76M outstanding shares and institutions hold larger chunk of about 84.40% of that.
The stock has a current market capitalization of $210.25M and its 3Y-monthly beta is at 2.02. It has posted earnings per share of -$1.57 in the same period. It has Quick Ratio of 3.69 while making debt-to-equity ratio of 0.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MGNX, volatility over the week remained 4.80% while standing at 5.57% over the month.
Analysts are in expectations that Macrogenics Inc (MGNX) stock would likely to be making an EPS of -0.66 in the current quarter, while forecast for next quarter EPS is -0.79 and it is -2.77 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.96 which is -0.42 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.75 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -697.81% while it is estimated to decrease by -83.92% in next year.
On July 31, 2024, Guggenheim Downgrade their recommendations, while on July 31, 2024, B. Riley Securities Downgrade their ratings for the stock with a price target of $5. Stock get a Hold rating from TD Cowen on May 10, 2024.
